Abstract
Platelet and vascular stimulation leads to release of reactive oxygen species (ROS) that are known to influence vascular reactivity and thrombosis. Dipyridamole is a vasodilator and platelet inhibitor that has previously been shown to have direct antioxidant properties. The antioxidant effects of dipyridamole on vascular cell-derived ROS are not known; therefore, dipyridamole was incubated with endothelial cells and platelets and cellular redox status and release of endogenous ROS were assessed. Dipyridamole decreased intracellular basal ROS generation from endothelial cells as measured by DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) oxidation. Incubation of endothelial cells with dipyridamole also attenuated t-butylhydroperoxide-induced oxidative stress. Using a redox-sensitive fluorescent dye, dipyridamole improved cellular activity after treatment with t-butylhydroperoxide. Incubation with dipyridamole did not alter platelet release of nitric oxide or hydrogen peroxide but significantly attenuated superoxide release. Using flow cytometry and confocal microscopy, dipyridamole decreased platelet ROS generation. Dipyridamole also suppressed platelet-soluble CD40 ligand release. In summary, at therapeutically relevant concentrations, dipyridamole suppresses the formation of ROS in platelets and endothelial cells and improves cellular redox status. These data suggest that the redox-dependent properties of dipyridamole have a direct effect on vascular cells.
Footnotes
-
This work was supported in part by National Institutes of Health Grants RO1AG08226 (to J.F.) and RO1HL62267 (to J.F.) and an Established Investigator Award from the American Heart Association (to J.F.). These studies were also funded by an unrestricted grant from Boehringer Ingelheim USA.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.089987.
-
ABBREVIATIONS: DCFDA, 2′,7′-dichlorodihydrofluorescein diacetate; CMDCFDA, 5- and 6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester; DPPH, 1,1-diphenyl-2-picrylhydrazyl; TRAP1-6, thrombin receptor-activating peptide; sCD40L, soluble CD40 ligand; PMA, phorbol 12-myristate 13-acetate; DMEM, Dulbecco's modified Eagle's medium; FRAP, ferric-reducing antioxidant power; DMSO, dimethyl sulfoxide; BAEC, bovine aortic endothelial cells; NO, nitric oxide; ROS, reactive oxygen species; DHR, dihydrorhodamine; eNOS, endothelial NO synthase.
- Received May 24, 2005.
- Accepted July 19, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|